课题基金 / 基金详情

ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F

ACTG316 NEVIRAPINE VS NEVIRAPINE PLACEBO FOR PREVENTION OF MATERNAL F
ACTG316 奈韦拉平与奈韦拉平安慰剂预防孕产妇妊娠的比较
批准号：
6306613
负责人：
MARGARET A KELLER
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6306613
关键词：
AIDS therapy HIV infections birth clinical research communicable disease control drug screening /evaluation female human pregnant subject human subject human therapy evaluation nevirapine vertical transmission

项目摘要

项目成果

MARGARET A KELLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To see if a new drug called Nevirapine is effective, when given to HIV-infected women during active labor and to their babies, in reducing transmission of HIV from mother to their babies. There is a need to develop altrnative and more potent antiretroviral therapies for use alone and in combination for the further reduction of perinatal transmission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS HIV
INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL DRUG COMBINATIONS
Two-Dimensional 3 Tesla MRS of the Brain in HIV- Infected Youth
PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL THERAPY DURING PREGNANCY
海外基金